Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 11, 2024

Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

Author(s)Ryan Haumschild, PharmD, MS, MBA, Marwan Fakih, MD , Michael Morse, MD, MHS, FACP

Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.

Episodes in this series

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Provide a brief overview of our therapy options in metastatic colorectal cancer that has progressed after FOLFOX/FOLFIRI.

Discuss the importance of biomarker screening.
A majority of patients will not have targetable biomarkers, so provide emphasis on the 3 therapies: regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man coughing. | Image credit: @sebra_AdobeStock.jpeg

CHMP Backs Nerandomilast for IPF and PPF in EU

BySabrina McCrear

June 10th 2026

From Patient Selection to Future Therapies: JAK Inhibitors in Alopecia Areata

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

Deuruxolitinib in Alopecia Areata: Trial Data, Onset of Action, and Adverse Event Management

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

Comparing the Clinical Trials of Baricitinib and Ritlecitinib in Alopecia Areata

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

JAK Inhibitors in Alopecia Areata: Clinical Rationale and FDA-Approved Therapies

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

ACA Enrollment Erosion Deepens After Open Enrollment Ends

Efgartigimod Effective in Broad Subsets of Patients With gMG

Alopecia Areata Takes a Hidden Toll on Work, Relationships, and Self-Care